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Abstract
Equine infectious anemia virus (EIAV) is a lentivirus that causes persistent infections in horses. We hypothesized that high-avidity CTL
specific for nonvariable epitopes might be associated with low viral load and minimal disease in EIAV-infected horses. To test this
hypothesis, memory CTL (CTLm) responses were analyzed in two infected horses with high plasma viral loads and recurrent disease
(progressors), and in two infected horses with low-to-undetectable viral loads and mild disease (nonprogressors). High-avidity CTLm in one
progressor recognized an envelope gp90 epitope, and the data documented for the first time in EIAV that viral variation led to CTL escape.
Each of the nonprogressors had high-to-moderate avidity CTLm directed against epitopes within Rev, including the nuclear export and
nuclear localization domains. These results suggested that the epitope specificity of high- and moderate-avidity CTLm was an important
determinant for disease outcome in the EIAV-infected horses examined.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Horses infected with equine infectious anemia virus
(EIAV) usually develop recurrent episodes of plasma vire-
mia and associated acute clinical disease (fever, inappe-
tence, lethargy, thrombocytopenia, and anemia) during the
first few months of infection (Cheevers and McGuire, 1985;
Montelaro et al., 1993; Sellon et al., 1994). In contrast to
other lentiviral infections, including human immunodefi-
ciency virus-1 (HIV-1), most, but not all, horses control
EIAV replication within a year and remain persistently
infected inapparent carriers (Cheevers and McGuire, 1985;
Montelaro et al., 1993; Sellon et al., 1994). Results of EIAV
infection in severe combined immunodeficient (SCID) Ara-
bian foals, and recently, immune reconstitution in a SCID
foal prior to EIAV challenge, indicate that this control of
viral replication is mediated by viral-specific immune re-
sponses (Perryman et al., 1988; Crawford et al., 1996;
Mealey et al., 2001).
Although the precise immunological mechanisms by
which horses control EIAV infection are unknown, evi-
dence exists that CD8 major histocompatibility complex
(MHC) class I restricted viral-specific cytotoxic T Lympho-
cytes (CTL) are important. Neutralizing antibodies un-
doubtedly play an antiviral role, but the initial plasma vire-
mia in acute EIAV infection is often terminated prior to the
appearance of neutralizing antibody (McGuire et al., 1990),
but concurrent with the appearance of CTL (McGuire et al.,
1994). Similarly, CTL are associated with control of the
primary viremia in HIV-1-infected people (Borrow et al.,
1994), while neutralizing antibody is not detected for up to
2 months after the primary viremia subsides (Pantaleo and
Fauci, 1995). The adoptive transfer of autologous CTL
clones to HIV-1-infected patients results in functional CTL
activity in infected tissues and transiently reduces the levels
of circulating productively infected CD4 T lymphocytes
(Brodie et al., 1999). Additionally, transfer of CTL clones to
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HIV-1-infected (hu)-PBL-SCID mice reduces plasma vire-
mia (McKinney et al., 1999). Direct evidence for CD8
lymphocyte control of simian immunodeficiency virus
(SIV) in infected rhesus monkeys is provided by in vivo
depletion of CD8 lymphocytes with monoclonal antibody
(Schmitz et al., 1999; Jin et al., 1999). Moreover, vaccines
that induce high-frequency SIV-specific CTL responses in
rhesus monkeys result in reduced viral loads and prevention
of clinical AIDS following pathogenic SIV challenge (Ba-
rouch et al., 2000, 2001a,b). Horses recently infected with
EIAV have CD8 effector CTL (CTLe) in peripheral blood
mononuclear cells (PBMC), which do not require in vitro
stimulation for effector function (McGuire et al., 1994).
These CTL recognize epitopes in Env and Gag proteins
(McGuire et al., 1994). Later in infection, when the horses
have controlled viremic episodes and are inapparent carri-
ers, memory CTL (CTLm) to Env and Gag proteins which
require in vitro stimulation are present (Hammond et al.,
1997; McGuire et al., 1997). These CTLm have a mean
frequency of 293 per million PBMC (McGuire et al., 1997).
CTLm epitopes have been identified in EIAV Gag, Pol,
Env, and in the protein encoded by the S2 open reading
frame (Lonning et al., 1999; McGuire et al., 2000; Zhang et
al., 1998).
Following acute infection, recurrent viremic episodes are
associated with the emergence of antigenically distinct
EIAV variants as defined by neutralizing antibody (Kono et
al., 1973; Rwambo et al., 1990). Studies suggest that im-
mune pressure exerted by neutralizing antibody selects for
antigenic variation in envelope glycoprotein epitopes, re-
sulting in escape from humoral responses (Leroux et al.,
2001; Montelaro et al., 1984; Payne et al., 1987; Ball et al.,
1992). Ongoing envelope variation continues during long-
term asymptomatic infection (Leroux et al., 2001). How-
ever, because variant EIAV isolates can be detected prior to
neutralizing antibody, it is unlikely that humoral immune
selection is the only factor in their genesis (Carpenter et al.,
1987; Hussain et al., 1987; Rwambo et al., 1990), and it is
possible that lymphocyte-mediated immune selection is in-
volved in the appearance of these genetically distinct virus
isolates. The fact that recurrent episodes of viremia and
clinical disease occur in the face of both neutralizing anti-
body and CTL suggests that EIAV variants arise that must
escape both neutralizing antibody and CTL responses. It has
been well documented that CTL epitope escape variants
occur during HIV-1 infection (Borrow et al., 1997; Harrer et
al., 1998) and that variation in HIV-1 CTL epitopes results
in loss of cytotoxic activity and is associated with clinical
progression to AIDS (Goulder et al., 1997a; Koenig et al.,
1995).
Some EIAV-infected horses, designated nonprogressors,
control the initial viremia and subsequently maintain low or
undetectable plasma viral loads and remain free of episodic
clinical disease (Leroux et al., 2001). In HIV-1-infected
nonprogressors, high levels of CTL activity have been as-
sociated with the lack of disease progression (Harrer et al.,
1996; Rinaldo et al., 1995). In addition, it has been shown
in HIV-1 and lymphocytic choriomeningitis virus (LCMV)
models in mice that the ability of CTL to clear virus in vivo
cannot be predicted simply by the ability of CTL to kill
infected targets. Rather, in vivo efficacy is dependent on
functional avidity: the ability of CTL to kill targets express-
ing low antigen density (Alexander-Miller et al., 1996;
Derby et al., 2001a; Gallimore et al., 1998a). Interestingly,
recent evidence suggests that CTL with high functional
avidity rapidly select for CTL escape SIV variants
(O’Connor et al., 2002).
Given the above observations, we hypothesized that
CTLm with high functional avidity directed against nonva-
riable epitopes would occur in EIAV-infected nonprogres-
sor horses. To test this hypothesis, the CTLm responses in
four EIAV-infected Arabian horses were analyzed over a
1.7-year period. Two horses were considered nonprogres-
sors based on minimal clinical disease and low-to-undetect-
able plasma viral loads as measured by real-time quantita-
tive RT-PCR. In these two horses, CTLm with high and
moderate avidities directed against epitopes in Rev were
identified. Interestingly, the Rev epitopes included portions
of the nuclear export and nuclear localization domains. The
other two horses were considered progressors based on
high-plasma viral loads and recurrent episodes of disease.
Unexpectedly, high-to-moderate avidity CTLm were also
identified in both horses. In one progressor, high-avidity
CTLm were directed against an epitope in the highly vari-
able putative principle neutralizing domain of envelope
gp90, and viral variation within the epitope led to loss of
CTLm recognition. These results suggest that in addition to
functional avidity, the EIAV proteins targeted by CTLm are
critical in determining disease outcome.
Results
EIAV-induced disease progression and plasma viral loads
Clinical disease status and plasma viral loads over a
1.7-year period revealed that two horses (A2140 and
A2147) experienced recurrent disease (Fig. 1), while the
other two horses (A2150 and A2153) experienced minimal
disease following resolution of the first viremic episode
(Fig. 2).
The first of the two horses considered progressors, horse
A2140, had six disease episodes (V1–V6) beginning on
days postinoculation (DPI) 24, 178, 285, 348, 418, and 500.
The other progressor, horse A2147, had 16 disease episodes
(V1–V16) beginning on DPI 9, 110, 145, 282, 309, 351,
386, 400, 428, 442, 470, 498, 519, 540, 575, and 610. For
both A2140 and A2147, thrombocytopenic disease episodes
were almost always associated with fever and other clinical
signs of EIAV-induced disease (inappetence and lethargy).
The first of the two horses considered nonprogressors,
A2150, had only two disease episodes (V1 and V2) begin-
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ning on DPI 9 and 568. An episode of thrombocytopenia
occurred on DPI 26 that was not associated with detectable
plasma viral RNA (nor fever) and was not considered a
distinct disease episode. The thrombocytopenia may have
been due to residual bone marrow suppression associated
with V1. Another thrombocytopenic episode occurred on
DPI 407, which again was not associated with detectable
plasma viral RNA (nor fever), and therefore, was not con-
sidered a distinct disease episode. Plasma virus was detected
on DPI 222, but was not associated with any clinical dis-
ease. None of the episodes of thrombocytopenia (including
V1 and V2) in horse A2150 were associated with fever or
other signs of clinical disease. The other nonprogressor,
horse A2153, had only two disease episodes (V1 and V2),
early in infection, beginning on DPI 9 and 28. Horse A2153
had only mild fever (38.7°C) associated with V1 only, and
never experienced any other clinical signs attributable to
EIAV.
Viral load was determined in plasma samples obtained
during clinical disease episodes, and at various other time
points between episodes (Figs. 1 and 2). Plasma viral RNA
was detected in progressor horses A2140 and A2147 plasma
on 70% (14/20) and 95% (19/20) of the days assayed,
respectively. Plasma viral load was variable in A2140, rang-
ing from undetectable to 7.1  104 RNA copies/ml,
whereas in A2147, the viral load appeared to reach a steady
state of approximately 3  105 RNA copies/ml after V4. In
contrast, plasma virus was detected in nonprogressor horses
A2150 and A2153 plasma on only 13.6% (3/22) and 17.6%
(3/17) of the days assayed, respectively. For A2150, viral
load values were 2.7  105 and 7.5  101 RNA copies/ml
for V1 and V2, respectively. The only other positive sample
was obtained on DPI 222, which contained 1.1  104 RNA
copies/ml. For A2153, viral load values ranged from 1.2 
103 to 2.7  105 RNA copies/ml during V1 and V2, but
viral RNA could not be detected thereafter.
CTLm analysis in nonprogressors A2140 and A2147
CTLm epitope mapping in A2140
To determine the EIAV proteins recognized by CTLm,
equine kidney (EK) cells were transduced with retroviral
vectors expressing either whole EIAV proteins or polypep-
tides (McGuire et al., 2000) and used as CTL targets. CTLm
in PBMC obtained after V1 from A2140 recognized targets
expressing the N-terminal third of the envelope protein
which includes a part of the gp90 surface unit (SU), and
Figs. 1. Clinical disease progression and plasma viral load in horses A2140 and A2147. Rectal temperatures above the horizontal line were considered febrile
(38.6°C), while platelet counts below the horizontal line were considered thrombocytopenic (150,000 platelets/l whole blood). Clinical disease was
defined as thrombocytopenia with or without fever, concurrent with detectable plasma virus. Plasma EIAV RNA copies/ml are indicated with “*”. Samples
in which virus was not detected are indicated with “” on the x-axis.
539R.H. Mealey et al. / Virology 313 (2003) 537–552
targets expressing the Gag p15 protein (McGuire et al.,
2000).
To further analyze the envelope epitope, CTL assays
were performed using EK cell targets transduced with
retroviral vectors expressing envelope polypeptide trun-
cations (McGuire et al., 2000). The epitope was con-
tained in SU, and to identify the minimal epitope, over-
lapping peptides were synthesized and used to sensitize
EK target cells. The 12-mer CTLm epitope (RVEDVT-
NTAEYW) spanned amino acids (aa) positions 195 to
206 in the EIAVWSU5 envelope protein and was desig-
nated Env195-206RW12 (Table 1). The arginine in position
1 was considered a probable anchor residue, since its
omission resulted in a 4 log10 reduction in target cell
recognition efficiency. CTL assays using peptide-pulsed
ELA-A1 and ELA-w11 half-matched EK target cells in-
dicated that presentation of Env-RW12 was associated
with the ELA-A1 haplotype.
A similar strategy was used to identify the A2140 CTLm
epitope within Gag p15. The epitope (GSQKLTTGNCNW)
spanned aa positions 21 to 32 in the EIAVWSU5 Gag protein
and was designated Gag21-32GW12 (Table 1). CTL assays
using peptide-pulsed ELA-A1 and ELA-w11 half-matched
EK target cells indicated that Gag-GW12 was restricted by
the ELA-A1 haplotype.
EIAV CTLm epitope escape variants in A2140
Because the Env-RW12 epitope was located within the
putative principle neutralizing domain (PND) of EIAV
gp90, a region known to be highly variable (Ball et al.,
1992), it was possible that viral variation within the epitope
could have resulted in loss of CTLm recognition. In addi-
tion, natural variation in EIAV Gag regions that contain
CTL epitopes is known to occur (Zhang et al., 1999), raising
the possibility that variation within the Gag-GW12 epitope
could also have resulted in loss of CTLm recognition.
Analysis of deduced aa sequences of EIAV clones ob-
tained from A2140 V5 plasma indicated that viral variation
occurred in the Env-RW12 epitope (Fig. 3a). None of the
observed aa changes were present in the virus stock used for
inoculation (Fig. 3b). The majority of the Env-RW12 vari-
ants (59%; 13/22 clones) had the sequence HVKDET-
NTTEYW, which was designated Env195-206HW12v (Table
1). The aa substitution at position 1 (R 3 H) involved a
suspected anchor residue. The other aa changes within the
epitope involved residues likely important for T cell recep-
Fig. 2. Clinical disease progression and plasma viral load in horses A2150 and A2153. Rectal temperatures above the horizontal line were considered febrile
(38.6°C), while platelet counts below the horizontal line were considered thrombocytopenic (150,000 platelets/l whole blood). Clinical disease was
defined as thrombocytopenia with or without fever, concurrent with detectable plasma virus. Plasma EIAV RNA copies/ml are indicated with “*”. Samples
in which virus was not detected are indicated with “{” on the X-axis.
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tor (TCR) binding and included both conservative and non-
conservative substitutions. This variant peptide was synthe-
sized and used to sensitize EK target cells for CTL assays.
A2140 CTLm obtained after V5 failed to lyse targets pulsed
with Env-HW12v (Fig. 3c). The result was the same when
CTLm obtained between V1 and V2 (at 47 DPI) were used
(data not shown). In addition, Env-HW12v was incapable of
stimulating CTLm to lyse either Env-RW12- or Env-
HW12v-sensitized target cells.
Because two possible neutralizing antibody binding sites
(ENT and DNT) (Ball et al., 1992) span the Env-RW12
epitope, it was of interest to attempt to determine whether
Env-HW12v was the result of selection pressure exerted by
neutralizing antibody or CTL. Neutralizing antibody activ-
ity directed against the EIAVWSU5 inoculum was present in
DPI 285 (V3) and DPI 45 (between V1 and V2) plasma
(100% and 95% virus reduction, respectively), but was
absent in DPI 24 (V1) plasma (4% virus reduction). Pre-
incubation of DPI 45 plasma with peptides containing both
putative neutralizing antibody epitopes was done using se-
rial 10-fold dilutions of both peptides in plasma starting
with a concentration of 1 mg/ml. These peptides failed to
block neutralizing antibody activity in DPI 45 plasma, sug-
gesting either that the Env-RW12 region was not a target for
neutralizing antibody or that additional neutralizing anti-
body epitopes were present outside this region. Analysis of
cloned EIAV sequences from plasma obtained during V1
(DPI 24), V2 (DPI 178), between V2 and V3 (DPI 230) and
V3 (DPI 285) indicated that aa changes within the Env-
RW12 epitope, which included a change in the suspected
N-terminal anchor residue, occurred as early as DPI 24,
before neutralizing antibody was detected (Fig. 3d). CTLm
from before DPI 47 were not available for study. The aa
changes within the epitope became more pronounced at the
later time points, and it is possible that both CTL and
neutralizing antibody were involved in their genesis. Re-
gardless of the cause, significant aa variation occurred
within Env-RW12 that abrogated the CTLm response and
likely contributed to the recurrent disease experienced by
A2140.
Deduced aa sequences of EIAV clones obtained from
A2140 V5 plasma were also analyzed to determine whether
viral variation occurred within the Gag-GW12 CTLm
epitope (Fig. 3e). Of these clones, 61% (11/18) had the
sequence GSQKLSTGNCNW, while 39% (7/18) had the
sequence GSQKLNTGNCNW. The aa substitutions at po-
sition 6 were conservative in both variants. These two
CTLm epitope variant peptides were synthesized (Table 1)
and used to sensitize EK target cells. CTLm from between
V1 and V2 (DPI 47) recognized Gag-GW12 as well as both
variants. CTLm obtained after V5 and stimulated with pep-
tide Gag-GW12 actually recognized both variants more
efficiently than Gag-GW12, and each of the variants were
capable of stimulating CTLm, with the GSQKLSTGNCNW
variant being most efficient (data not shown). It was con-
cluded that even though viral variation through the Gag-
GW12 epitope occurred, CTLm responses were not dimin-
ished and were eventually enhanced.
CTLm epitope mapping in A2147
The same panel of retroviral vectors was used to trans-
duce target cells for initial identification of EIAV proteins
with epitopes recognized by A2147 CTLm. Overlapping
Gag p26 peptides (Zhang et al., 1998) were then used to
sensitize target cells, and the optimal CTLm epitope
(FVDRLLSQIK) spanned aa positions 288 to 297 in the
EIAVWSU5 Gag protein and was designated Gag288-297FK10
(Table 1). This epitope was restricted by the ELA-A4 hap-
lotype.
Gag protein recognition by CTLm from A2147 was first
characterized after V5 (before V6), but the exact time point
Table 1
CTLm epitopes (and synthesized epitope variant peptides) identified in EIAVWSU5-infected horses A2140, A2147, A2150, and A2153
CTLm epitope
designation
(abbreviated)
No.
of aa
aa Sequence ELA-A
restriction
EIAV
protein (aa
positions)
Overall
avidity
(nM)
Synthesized
variant peptide
designation
(abbreviated)
Synthesized
variant
peptide aa
sequence
Horse Progressor/
nonprogressor
Env195–206RW12 12 RVEDVTNTAEYW A1 Env 0.21 Env195–206HW12v HVKDETNTTEYW A2140 Progressor
Env-RW12 195–206 Env-HW12v
Gag21–32GW12 12 GSQKLTTGNCNW A1 Gag 155 None assigned GSQKLSTGNCNW A2140 Progressor
Gag-GW12 21–32 GSQKLNTGNCNW
Gag288–297FK10 10 FVDRLLSQIK A4 Gag 18.7 None None A2147 Progressor
Gag-FK10 288–297
Rev57–67QW11 11 QAEVLQERLEW A1 Rev 0.29 None None A2150 Nonprogressor
Rev-QW11 57–67
Rev120–131PR12 12 PRVLRPGDSKRR A1 Rev 5658 None synthesized None synthesized A2150 Nonprogressor
Rev-PR12 120–131
Rev24–33R10 10 IPSQTCITRR Not determined Rev 47.8 None synthesized None synthesized A2153 Nonprogressor
Rev-IR10 24–33
Rev104–112GR9 9 GGYQRAQER Not determined Rev 25.1 None synthesized None synthesized A2153 Nonprogressor
Rev-GR9 104–112
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at which the Gag-FK10 CTLm first appeared is not known.
Given the EIAV variation observed previously in Gag
CTLm epitopes, plasma EIAV RT-PCR products from sev-
eral disease episodes (V1, V2, V3, V10, and V14) were
sequenced. No aa variation was observed in the Gag-FK10
epitope recognized by CTLm from A2147 (data not shown).
CTLm analysis in nonprogressors A2150 and A2153
CTLm epitope mapping in A2150 and A2153
The same panel of retroviral vectors was used to trans-
duce target cells for initial identification of EIAV proteins
with epitopes recognized by A2150 and A2153 CTLm. For
Fig. 3. (a) Deduced EIAV envelope gp90 amino acid sequences (aa 122-238) obtained from A2140 V5 plasma (GenBank Accession Nox. AY288526-
AY288549) as compared to the EIAVWSU5 stock used for inoculation. Only those aa different from those in EIAVWSU5 are shown. rtpcr1 and rtpcr2 were
two different directly sequenced RT-PCR products. Clones designated with a “1.” were derived from the rtpcr1 product, while clones designated with a “2.”
were derived from the rtpcr2 product. The Env-RW12 CTLm epitope is in bold and underlined. The hypervariable regions V2 and V4, the putative principle
neutralizing domain (PND), and the two murine monoclonal neutralizing antibody epitopes ENT and DNT (Ball et al., 1992) are indicated. (b) Deduced EIAV
envelope gp90 amino acid cloned sequences (aa 122-238) obtained from the EIAVWSU5 stock used for inoculation (GenBank Accession Nos. AY288550-
AY288559). Only those aa different from the EIAVWSU5 consensus are shown. The Env-RW12 CTLm epitope is in bold and underlined. (c) A2140 CTLm
were added to homologous EK targets pulsed with either peptide Env-RW12 or Env-HW12v at the concentrations indicated. CTLm were from PBMC
obtained after V5 and stimulated for 7 days with EIAVWSU5. Effector:target cell ratio was 20:1. (d) Deduced EIAV envelope gp90 amino acid sequences
(aa 182-238) obtained from A2140 V1 (DPI 24), V2 (DPI 178), between V2 and V3 (DPI 230), and V3 (DPI 285) plasmas (GenBank Accession Nos.
AY288560-AY288587) as compared to the EIAVWSU5 stock used for inoculation. Only those aa different from those in EIAVWSU5 are shown. Clones are
designated by the DPI from which the RT-PCR product was obtained, followed by the clone number. The Env-RW12 CTLm epitope is in bold and underlined.
(e) Deduced EIAV Gag p15 amino acid sequences (aa 3-57) obtained from A2140 V5 plasma (GenBank Accession Nos. AY288588-AY288605) as
compared to the EIAVWSU5 stock used for inoculation. Only those aa different from those in EIAVWSU5 are shown. The Gag-GW12 CTLm epitope is in bold
and underlined.
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both horses, only EK targets expressing Rev were lysed by
CTLm obtained shortly after V1. To identify the epitopes
within Rev, overlapping peptides were synthesized and used
to sensitize EK target cells.
CTLm from A2150 recognized two distinct epitopes with-
in Rev. The first (QAEVLQERLEW) spanned aa positions
57-67 of EIAVWSU5 Rev and was designated Rev57-67QW11
(Table 1). The second (PRVLRPGDSKRR) spanned aa
positions 120-131 of EIAVWSU5 Rev and was designated
Rev120-131PR12 (Table 1). Both epitopes were restricted by the
ELA-A1 haplotype. CTLm from A2153 also recognized two
distinct Rev epitopes, and the minimal epitopes were
designated Rev24-33IR10 (IPSQTCITRR), spanning aa posi-
tions 24-33 of EIAVWSU5 Rev, and Rev104-112GR9
(GGYQRAQER), spanning aa positions 104-112 of EIA-
VWSU5 Rev (Table 1). The restricting MHC class I haplotypes
were not determined for either of the two Rev-specific CTLm
epitopes identified in A2153.
Variation in Rev epitopes recognized by A2150 and
A2153
Because genetic and biological variation is known to
occur in EIAV Rev during infection (Belshan et al.,
2001), it was of interest to determine the plasma viral
Rev sequences in A2150 and A2153. Since both horses
had low or undetectable plasma viral load, nested RT-
PCR was used to amplify EIAVWSU5 Rev sequences from
plasma viral RNA in A2150 (DPI 568 plasma) and A2153
(DPI 575 plasma).
In A2150 DPI 568 plasma, 25 of 25 and 13 of 25 cloned
Rev sequences were identical to the inoculum consensus
sequence (Fig. 4) through the Rev-QW11 and Rev-PR12
CTLm epitopes, respectively (Fig. 5a). In A2153 DPI 575
plasma, 17 of 23 and 16 of 23 cloned Rev sequences were
identical to the inoculum consensus sequence through the
Rev-IR10 and Rev-GR9 epitopes, respectively (Fig. 5b).
Functional avidity for Env-RW12-, Gag-GW12-, and Gag-
FK10-specific CTLm in progressors A2140 and A2147
For all CTLm epitopes, the functional avidity values
varied with the peptide concentration used for CTLm stim-
ulation. The Env-RW12-specific CTLm exhibited high
functional avidity values ranging from 0.06 to 1.5 nM (Fig.
6a), with a geometric mean of 0.21 nM representing the
overall functional avidity. For Gag-GW12, CTLm func-
tional avidity was moderate and ranged from 64.7 to 253
nM (Fig. 6b), with a geometric mean of 155 nM. The
Gag-FK10-specific CTLm were also of moderate functional
avidity, with values ranging from 14.1 to 25.3 nM (Fig. 6c)
and a geometric mean of 18.7 nM.
Functional avidity for Rev-QW11-, Rev-PR12-, Rev-IR10-,
and Rev-GR9-specific CTLm in nonprogressors A2150
and A2153
The Rev-QW11-specific CTLm exhibited high func-
tional avidity values ranging from 0.09 to 1.4 nM (Fig. 6d),
with a geometric mean of 0.29 nM. For Rev-PR12, CTLm
functional avidity was low and ranged from 3177 to 8345
nM (Fig. 6e), with a geometric mean of 5658 nM. The
Rev-IR10-specific CTLm were of moderate functional avid-
ity, with values ranging from 35.4 to 156 nM (Fig. 6f) and
a geometric mean of 47.8 nM. For Rev-GR9, CTLm func-
tional avidity was also moderate and ranged from 38.2 to
45.5 nM (Fig. 6g), with a geometric mean of 25.1 nM.
Overall CTLm functional avidity comparisons
Analysis of functional avidity vs stimulation peptide
concentration curves indicated that each peptide-specific
CTLm line could be differentiated from the others at most
peptide concentrations used for stimulation (Fig. 7). CTLm
with high overall functional avidity (geometric mean) oc-
curred in one of the nonprogressors (Rev-QW11 in A2150)
and in one of the progressors (Env-RW12 in A2140), while
CTLm with moderate-to-low overall functional avidity oc-
curred in both groups (Table 1).
Fig. 4. Deduced amino acid sequences for Rev clones (aa 1-135) obtained from the EIAVWSU5 stock used for inoculation (GenBank Accession Nos.
AY288606-AY288624). Only those aa different from EIAVWSU5 consensus sequence are shown. The epitopes recognized by CTLm from A2150 and A2153
are indicated. The Y 3 H substitution at position 91 was present in 17/19 clones and was therefore used as the inoculum consensus for A2150 and A2153
plasma Rev alignments.
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Discussion
Horses infected with EIAV provide a unique outbred
model for the study of immunological control mechanisms
in a naturally occurring lentiviral disease. Although there is
strong evidence that CTL are a particularly important con-
trol mechanism, lentiviruses persist in the face of CTL. In
EIAV, CTL occur in association with the control of the
initial episode of plasma viremia and clinical disease, yet
clinical disease recurs during the first year of infection. To
further define the role of CTL in EIAV control, a detailed
analysis of EIAV-specific CTLm responses was done with
respect to epitopes recognized, quality (as measured by
functional avidity), and viral evasion, in horses with pro-
gressive and nonprogressive disease. Our results indicated
that CTLm functional avidity alone did not determine dis-
ease status, since high-avidity CTLm were found in the
progressor horses as well as in the nonprogressor horses.
However, CTLm from both nonprogressors targeted multi-
ple epitopes in Rev, an EIAV protein essential for viral
replication. In contrast, high-avidity CTLm in one of the
progressors were directed against an epitope within the
highly variable envelope gp90 protein, and our data pro-
vided the initial demonstration that EIAV variation of a
CTL epitope resulted in loss of CTL recognition.
The avidity of the interaction between CTL and their
target cells determines the efficiency with which CTL rec-
ognize and kill their specific targets (Gallimore et al.,
1998a). In comparison to low-avidity CTL, high-avidity
CTL of the same specificity recognize target cells express-
ing lower antigen density and initiate lysis of targets more
rapidly at any given antigen density (Derby et al., 2001a).
Adoptive transfer experiments in mice infected with LCMV
as well as in mice infected with vaccinia virus constructs
expressing HIV-1 proteins indicate that the in vivo protec-
tive effects of CTL correlate with their avidity (Alexander-
Miller et al., 1996; Derby et al., 2001a; Gallimore et al.,
1998a). Further studies in mice show that high-avidity CTL
are preferentially expanded during the active phase of viral
infection, but that low-avidity CTL are always more abun-
dant (Alexander-Miller, 2000). Surprisingly, a selective loss
of high-avidity CTL occurs in the CTL memory pool, and
Fig. 5. (a) Deduced amino acid sequences for cloned EIAV Rev variants (aa 1-135) obtained from A2150 DPI 568 plasma (GenBank Accession Nos.
AY288625-AY288649) and (b) A2153 DPI 575 plasma (GenBank Accession Nos. AY288650-AY288672) as compared to the EIAVWSU5 stock used for
inoculation. Only those aa different from those in EIAVWSU5 are shown. The nuclear export signal (NES) and putative nuclear localization signal (NLS)
(Fridell et al., 1993; Harris et al., 1998) are indicated, as are the CTLm epitopes. Sequences designated “b” were from clones derived from a second
independent nested RT-PCR reaction.
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thus, the ratio of low:high avidity CTLm may not reflect that
of CTLe found during the acute response (Alexander-
Miller, 2000). However, the CTL functional avidity estab-
lished at the peak of the effector response can be maintained
throughout the memory phase (Slifka and Whitton, 2001).
In the present study, functional avidity was determined
using the CTL memory pool, and it is possible that the
avidity of CTLe during active infection may have actually
been higher. Irregardless, it is likely that the relative pattern
of observed avidities of each of the CTLm lines would be
unchanged.
Although functional avidities of CTL specific for differ-
ent peptide epitopes have been compared (O’Connor et al.,
2002), antigen densities on antigen-presenting cells (APC)
or target cells are relative and vary for different peptides
depending on MHC binding affinity (Alexander-Miller et
al., 1996). In the present study, overall functional avidity
was determined for each individual peptide epitope-specific
CTLm line, over a range of stimulation peptide concentra-
tions. A range of peptide concentrations was used to stim-
ulate each CTLm line because a single peptide concentra-
tion may not have been optimal for every epitope, and
alternatively, may have been supra-optimal for others, lead-
ing to apoptosis of high-avidity CTLm (Derby et al.,
2001b).
Antiviral selection pressure imposed by CTL resulting in
CTL escape mutations is well described for HIV-1 and SIV
(Allen et al., 2000; O’Connor et al., 2002; Price et al., 1997;
Borrow et al., 1997; Chen et al., 2000; Goulder et al.,
1997a,b, 2001; Harrer et al., 1998; Kelleher et al., 2001). In
HIV-1, a narrow CTL response characterized by an immu-
nodominant clone is more likely to result in antigenic es-
cape and loss of viral control than a broad CTL response
directed against multiple epitopes (Wodarz and Nowak,
2000). Moreover, high-avidity CTL are more likely than
low-avidity CTL to rapidly select for escape variants fol-
lowing acute SIV infection in rhesus monkeys (O’Connor et
al., 2002). Based on the high level of killing and high
avidity displayed by the Env-RW12 CTL in A2140, the
Env-RW12 CTL response was probably immunodominant.
Fig. 6. (a–g) CTLm functional avidity. CTLm from each horse were stimulated for 7 days with the indicated peptides at 10 pM (0.00001 M) to 100 M
and then added at an effector:target cell ratio of 20:1 to homologous EK targets pulsed with the same peptides at 101-105 nM. Functional avidity is the
peptide concentration that results in 50% maximal target cell lysis and was not determined for CTLm stimulations resulting in maximum specific lysis less
than 10% above the % specific lysis of homologous target cells not pulsed with peptide. Peptide concentrations used to stimulate each CTLm subline are
shown in boxes.
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Given the highly variable nature of the gp90 region targeted
by these CTL, it is not surprising that the Env-HW12v CTL
escape variant arose.
In general, variation in EIAV gp90 has been attributed to
neutralizing antibody selection pressure (Ball et al., 1992;
Hussain et al., 1987, 1988; Leroux et al., 2001). Because the
Env-RW12 CTL epitope occurred within the putative PND,
it is possible that Env-HW12v was, in part, a neutralizing
antibody escape variant. Two contiguous linear murine
monoclonal neutralizing antibody epitopes have been
mapped to the EIAV PND (Ball et al., 1992), and they bisect
the Env-RW12 CTL epitope. Although serum antibodies
from EIAV-infected horses bind these same epitopes (Ball
et al., 1992; Hussain et al., 1988), there is no evidence that
these antibodies neutralize EIAV infectivity, and the pep-
tide epitopes recognized by EIAV-neutralizing antibodies
from EIAV-infected horses are unknown. Moreover, neu-
tralizing antibodies may not be critical in the selection of
EIAV antigenic variants (Rwambo et al., 1990). Similarly,
neutralizing antibodies are not likely involved in the genesis
of gp90 variants in the early stages of EIAV infection, and
regions other than the PND probably determine envelope
neutralizing properties in the later stages (Leroux et al.,
1997). In the present study, peptides containing the Env-
RW12 CTL epitope as well as the two known epitopes
recognized by murine monoclonal neutralizing antibodies
failed to block neutralizing antibody activity in A2140
plasma. Moreover, a probable MHC class I anchor residue
changed in the Env-RW12 CTL epitope before the appear-
ance of detectable neutralizing antibody. These observa-
tions suggest that the CTL epitope variant Env-HW12v was
the result of CTL selection pressure.
The variation observed in the Gag-GW12 CTLm epitope
was interesting in that CTLm recognition of one of the
variants was more efficient than the original epitope. Natu-
ral variation occurs in EIAV Gag proteins containing CTL
epitopes, including p15 and p26 (Zhang et al., 1999), and it
is possible that these variants are the result of CTL selection
pressure. The Gag-GW12 variants observed in the present
study could have originated secondary to CTL selection
pressure, but variant-specific CTL were subsequently in-
duced. Despite CTL recognition of these variants, disease
episodes were not controlled in A2140.
Horse A2147 had progressive disease despite moderate
avidity CTLm directed against a nonvariable epitope in Gag
p26. The Gag-FK10 CTLm were the only CTL identified in
A2147 and it is possible that effective viral control requires
higher numbers of CTL, or a CTL response directed against
epitopes in multiple viral proteins (Harrer et al., 1996).
Lymphocyte proliferation decreases during EIAV viremia
(Newman et al., 1991), and a reduced helper T lymphocyte
response might have contributed to the inability of the
Gag-FK10 CTL to control viral replication. Additionally,
CTL responses are inhibited by downregulation of MHC
Fig. 7. Overall functional avidities for each of the CTLm epitopes identified in A2140, A2147, A2150, and A2153. Overall functional avidity was defined
as the geometric mean of the range of functional avidity values determined for each peptide-specific CTLm line stimulated for 7 days with peptide
concentrations ranging from 10 pM to 100 M. Functional avidity was not determined for CTLm stimulations resulting in maximum specific lysis less than
10% above the % specific lysis of homologous target cells not pulsed with peptide.
546 R.H. Mealey et al. / Virology 313 (2003) 537–552
class I expression on APC during HIV-1 infection (Andrieu
et al., 2001), and there is preliminary information that this
occurs during EIAV infection in vitro (W. Maury, unpub-
lished observation). In A2140, the Gag-GW12 peptide ap-
peared to be subdominant to the Env-RW12 peptide, based
on the relative strengths of the corresponding CTL re-
sponses (as measured by % specific lysis). Subdominant
epitopes can be characterized by inefficient MHC class
I/peptide processing, unstable MHC class I/peptide binding,
and a CTL response that is not protective (Gallimore et al.,
1998b). It is therefore possible that the CTL response in
A2147 was ineffective because a subdominant Gag epitope
was exclusively targeted by CTL with moderate avidity.
Both nonprogressors had high- and low-avidity CTLm
(A2150) or moderate-avidity CTLm (A2153) directed
against multiple epitopes in Rev. Within infected cells, Rev
mediates the export of incompletely spliced viral RNA from
the nucleus and is absolutely required for expression of viral
structural genes and production of new virus (Belshan et al.,
2001). Discrete functional domains within Rev important
for nuclear localization and nuclear export include the nu-
clear localization signal (NLS) (Harris et al., 1998) and the
nuclear export signal (NES) (Fridell et al., 1993). Kinetic
studies using HIV-1 Rev-specific CTL clones have shown
that cytolysis occurs well before peak virus production and
that selection pressure exerted by these CTL in vitro can
result in a virus population with mutations in the Rev
epitope, abrogating the CTL killing (Van Baalen et al.,
1998). It has been suggested that a mutation in the HIV-1
Rev essential activation domain (analogous to the NES of
EIAV Rev) may have contributed to the lack of disease
progression in a long-term asymptomatic patient (Iversen et
al., 1995). Moreover, Rev-specific CTL have been inversely
correlated with rapid progression to AIDS (Van Baalen et
al., 1997). Rev variants arise during EIAV infection (Alex-
andersen and Carpenter, 1991; Belshan et al., 1998, 2001;
Leroux et al., 1997), and in one EIAV-infected pony a
statistical correlation exists between Rev activity and dif-
ferent stages of clinical disease (Belshan et al., 2001).
Analysis of deduced aa sequences from DPI 568 plasma
Rev clones indicated that no variation occurred through the
Rev-QW11 epitope recognized by CTLm from A2150,
while 12 of 25 clones contained two aa substitutions in the
carboxyl-terminus of epitope Rev-PR12 (also recognized by
A2150 CTLm). It is probable that the high-avidity CTLm
directed against the nonvariable Rev-QW11 epitope played
a role in limiting viral load and clinical disease in A2150. In
addition, the two aa substitutions within Rev-PR12 involve
the amino-terminal portion of the EIAV Rev NLS, and it is
possible that these variants had reduced replication effi-
ciency. These variants were not present among the clones
analyzed from the virus stock used for inoculation, and it is
possible that the Rev-PR12-specific CTL were involved in
their selection.
A low percentage of plasma Rev clones from A2153 DPI
575 plasma had aa substitutions within the Rev-IR10 (6 of
23 clones; 26%) and Rev-GR9 (7 of 23 clones; 30%) CTL
epitopes. The lack of significant CTL epitope variation,
coupled with the fact that the EIAV Rev NES was partially
contained within the Rev-IR10 epitope, may have contrib-
uted to the low viral load and lack of progressive disease in
A2153.
In summary, of four EIAVWSU5-infected horses, two
developed progressive disease while two maintained low
viral loads and had nonprogressive disease. In one progres-
sor horse, CTLm with high functional avidity directed
against a variable EIAV epitope likely led to CTL escape,
while moderate-avidity CTLm directed against a nonvari-
able epitope were not protective in the other progressor
horse. In the nonprogressor horses, CTLm with various
functional avidities were directed against several different
epitopes within EIAV Rev, a protein essential for viral
replication. Importantly, high-avidity CTLm targeted a non-
variable Rev epitope in one of the nonprogressor horses,
while moderate-avidity CTLm were directed against two
Rev epitopes in the other nonprogressor horse. A moderate-
to high-avidity CTL response directed against multiple non-
variable viral peptides which are expressed early in infec-
tion and are required for viral replication is likely to be
critical for lentiviral control. This study provided evidence
that in some EIAV-infected horses, the viral proteins tar-
geted by CTLm are as critical as functional avidity in the
control of viral load and clinical disease.
Materials and methods
Horses, EIAV infection, clinical evaluation, and sample
collection
Four yearling Arabian horses (A2140, A2147, A2150,
and A2153) were inoculated intravenously with 107 50%
tissue culture infective doses (TCID50) of the WSU5 strain
of EIAV (O’Rourke et al., 1988). The equine leukocyte
alloantigen (ELA)-A types of the four horses (Table 2) were
determined serologically (Bailey, 1980). The ELA-A locus
is the best-defined polymorphic MHC class I locus in the
horse (Antczak et al., 1986), but other polymorphic loci
likely exist (Ellis et al., 1995). Rectal temperature and
clinical status were recorded daily, and for the first month
postinfection, platelet counts were made on whole blood
collected every 2 days and then weekly thereafter. For
Table 2
ELA-A class I serotypes of horses A2140, A2147, A2150, and A2153
Horse ELA-A Serotype
A2140 A1/w11
A2147 A4a
A2150 A1/w11
A2153 A4a
a The second allele could not be determined serologically.
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determination of viral load, plasmas were collected and
stored at 80°C every 2 days for the first month postinfec-
tion and then weekly thereafter. Clinical EIAV disease ep-
isodes were defined when thrombocytopenia (platelets 
150,000/l blood) occurred with or without fever (rectal
temperature 38.6°C), concurrent with detectable plasma
viral RNA.
PBMC stimulations
PBMC were isolated (Zhang et al., 1998) from each
horse at various time points throughout the experiment and
stimulated in vitro for 7 days using autologous EIAVWSU5-
infected or peptide-pulsed monocytes (McGuire et al., 2000;
Zhang et al., 1998). Briefly, EIAVWSU5 in 17% fetal bovine
serum was added to the isolated PBMC in amounts equal to
a multiplicity of monocyte infection of 1, assuming that
PBMC were 5% monocytes. When PBMC were pulsed with
peptides, a peptide concentration of 40 M was used. Virus
(or peptide) and PBMC were incubated for 2 h at 37°C with
occasional mixing before centrifugation at 250 g for 10 min.
PBMC were then resuspended at 5  106/ml RPMI 1640
medium with 10% fetal bovine serum (FBS), 20 mM
HEPES, 10 g/ml gentamicin, and 10 M 2-mercaptoetha-
nol. Tissue culture flasks (175 cm2) were seeded with 40
ml/flask and incubated at 37°C with 5% CO2 for 7 days at
37°C. PBMC were also isolated, suspended in FBS with
10% DMSO, and frozen in liquid nitrogen for use in later
assays. When frozen PBMC were used, stimulations were
performed as above except that 10 U/ml recombinant hu-
man IL-2 and irradiated autologous PBMC stimulators were
added (Zhang et al., 1998).
CTLm epitope mapping
To determine the EIAV proteins with CTL epitopes,
CTL activity in the stimulated PBMC was first determined
in 51Cr release CTL assays using equine kidney target cells
transduced with retroviral vectors containing inserts that
span the entire EIAVWSU5 genome (Lonning et al., 1999;
McGuire et al., 2000; Zhang et al., 1998). Transduced EK
cells were selected with G418 sulfate before use as target
cells and then seeded into 96-well plates. Target cells were
labeled with 50 l/well DMEM with 5% calf serum and 25
Ci 51Cr/ml for 2 h at 37°C. After washing the plates, the
stimulated PBMC effectors were added at effector:target
cell ratios of 20:1 and incubated for 17 h, and 100 l
supernatant was removed to determine 51Cr release. Percent
specific lysis was calculated using the following formula:
percent specific lysis  [(E  S)/(M  S)]  100, where E
 the mean of three or six test wells, S  the mean
spontaneous release from three or six target cell wells with-
out effector cells, and M  the mean maximal release from
three or six target cell wells with 2% Triton X-100
(McGuire et al., 1994). The formula used to calculate stan-
dard error of the percent specific lysis accounts for the
variability of E, S, and M. After regions of the viral genome
containing CTL epitopes were known, peptides 20-25 aa in
length and overlapping by 8-11 aa, corresponding to the
epitope-containing regions, were synthesized by the Labo-
ratory for Biotechnology and Bioanalysis (Washington
State University, Pullman, WA). Target cells were sensi-
tized by pulsing normal EK cells with the synthetic peptides
at 105 nM for 2 h at 37°C in 96-well plates containing 50
l/well DMEM with 5% calf serum and 25 Ci 51Cr/ml.
Minimal epitopes were defined by sensitizing target cells
with truncated overlapping peptides based on the patterns of
recognition of the longer peptides.
CTLm functional avidity
PBMC were stimulated as above, except that PBMC
were seeded into 24-well plates at 2  106/ml. Tenfold
dilutions of peptides (ranging from 10 M to 10 pM)
corresponding to the minimal CTL epitopes were used to
stimulate CTLm. CTL assays were then performed using
target cells pulsed with 10-fold dilutions of peptides ranging
from 100 M to 100 pM. CTLm functional avidity was
defined as the peptide concentration that resulted in 50%
maximal target cell specific lysis (Alexander-Miller et al.,
1996; Derby et al., 2001a) and was used to describe the
effectiveness of CTLm-mediated killing, encompassing
TCR affinity and signaling, as well as the efficiency of
MHC-peptide binding. Since functional avidity is depen-
dent on the peptide concentration used for stimulation
(Alexander-Miller et al., 1996), and because CTLm were
stimulated with peptide prior to functional avidity determi-
nation, each epitope-specific CTLm line was stimulated
with several different peptide concentrations as described
above. This resulted in a range of functional avidities for
each epitope-specific CTLm line. Overall functional avidity
was calculated for each epitope-specific CTLm line, by
determining the geometric mean of the functional avidity
values of each of the corresponding individual sublines
generated by stimulation with decreasing concentrations of
peptide. The functional avidity of an individual subline was
not determined if the maximal specific lysis of peptide-
pulsed target cells was less than 10% above the specific
lysis of target cells not pulsed with peptide. For graphical
comparisons between CTLm of different peptide epitope
specificities, CTLm functional avidity curves were gener-
ated for each CTLm line by plotting the functional avidity
values against the corresponding peptide concentrations
used for CTLm stimulation. A CTLm line was considered to
be of high avidity if its overall avidity value was at least
10,000 times lower than that of the CTLm line with the
lowest overall avidity.
Plasma neutralizing antibody activity in A2140
Neutralizing antibody activity in frozen heparinized
plasma from A2140 was determined using a virus reduction
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method (Mealey et al., 2001). Briefly, 300 l heparinized
plasma was heat inactivated by incubation at 56°C for 30
min, then mixed with 300 l EIAVWSU5 (approximate titer
104 TCID50/ml) stock, and incubated for 1 h at 37°C. The
same was performed using negative control plasma from
four horses not infected with EIAV. For each plasma–virus
mixture, threefold serial dilutions were made, and titration
was performed in EK cell culture (O’Rourke et al., 1988).
Percentage virus reduction was calculated using the follow-
ing formula: % virus reduction  [(mean negative control
plasma titer  test plasma titer)/(mean negative control
plasma titer)]  100.
Viral RNA purification
Viral RNA was isolated from 140 l frozen EDTA
plasma using a QIAamp Viral RNA kit (Qiagen Inc., Chats-
worth, CA) (Leutenegger et al., 2001) and DNase I treated
on the spin column (DNase 1 set; Qiagen), eluted in 60 l
nuclease-free water, and frozen at20°C. Only heparinized
plasma was available for horse A2140 on several of the days
assayed. For these samples, viral RNA was extracted as
above, and then the eluates were treated with heparinase as
described (Lin et al., 1997).
Real-time quantitative RT-PCR
Real-time RT-PCR was used to determine plasma viral
load in each of the four horses by amplification of a 127-bp
segment (nt 2984-3110) of the EIAVWSU5 (GenBank
Accession No. AF247394) reverse transcriptase gene. The
following oligonucleotides were used: forward primer,
5-AGACATGGTAAAGAATCCAACCCTTAATG-3; re-
verse primer, 5-TCTAAACATCCCTTAGTATGAGCT-
GCTATGTG-3; and TaqMan (Applied Biosystems, Foster,
CA) probe, 5-TACTGTCAACCCTGGGACCCCTGAG-
CTCAT-3 (nt 3045-3074). The fluorescence reporter dye at
the 5 end of the TaqMan probe was FAM (6-carboxyfluo-
rescein) and the quencher dye at the 3 end was 6-car-
boxytetramethyl-rhodamine (TAMRA). An RNA standard
template was made by cloning EIAVWSU5 nt 2078-3152
(which included the reverse transcriptase gene) into pCR2.1
(designated pWRT8; Invitrogen, Carlsbad, CA), followed
by in vitro transcription of the HindIII-linearized pWRT8
using the RiboMax Large-Scale RNA Production Sys-
tem-T7 (Promega, Madison, WI). After transcription, RNA
was DNase I treated and purified using an RNeasy Mini Kit
(Qiagen). To quantitate the transcribed RNA template, an
aliquot of the transcript eluate, along with serial dilutions of
a known RNA standard (RNA Quantitation Kit; Sigma, St.
Louis, MO), were analyzed by electrophoresis through a 1%
agarose gel containing 0.15 g/ml ethidium bromide. Be-
fore loading the gel, the RNA in each of the standard
dilutions was denatured by heating at 65°C for 10 min in a
mixture of 1.3 M formaldehyde, 11.8 M deionized form-
amide, 21.4 mM HEPES, and 1.1 mM EDTA disodium. The
integrated density value of the RNA bands in the gel was
determined using an AlphaImager 2000 digital imaging
system (Alpha Innotech Corp., San Leandro, CA). The
equation of the best-fit regression line for the integrated
density values of the known RNA standard dilutions was
used to calculate the RNA concentration in the transcript
eluate. The RNA transcripts were serially diluted to yield
106, 105, 104, 103, 102, 101, and 100 RNA copies/10 l in
nuclease-free water and stored in 25 l aliquots at 80°C.
Real-time RT-PCR was performed using the Platinum
Quantitative RT-PCR ThermoScript One-Step System (Life
Technologies, Gaithersburg, MD) in 25 l reactions con-
taining 12.5 l 2 ThermoScript Reaction Mix, 0.75 l
forward primer (25 M), 0.75 l reverse primer (25 M),
0.5 l TaqMan probe (10 M), 0.5 l ThermoScript Plus
RT/Platinum Taq Enzyme Mix, and 10 l RNA sample or
standard. Cycling conditions were 15 min at 50°C, 3.5 min
at 95°C, followed by 50 cycles at 95°C for 15 s and 60°C for
1 min. Reactions were carried out in duplicate in an iCycler
96 Thermal Cycler using the iCycler iQ Real-Time PCR
Detection System and software (Bio-Rad Laboratories, Her-
cules, CA). Real-time fluorescence measurements were per-
formed and a threshold cycle (CT) value for each sample
was calculated by determining the point at which the fluo-
rescence exceeded a threshold limit (10 times the standard
deviation of the baseline as determined between cycles 3
and 15). The CT value was proportional to the log of the
starting amount of nucleic acid and reflected the earliest
point in the amplification curve that could be used for
quantitation of the template input (Heid et al., 1996; Leu-
tenegger et al., 2001). The sensitivity of the real-time RT-
PCR was determined using a dilution series of the standard
RNA transcripts as above. The dilution containing 1 RNA
copy was positive in 40% (4/10) of the replicates, while the
dilutions containing 10 RNA copies or more were positive
in 100% (10/10) of the replicates. The reliable detection
limit, therefore, was somewhere between 43 and 428 RNA
copies/ml when 140 l plasma for the RNA extraction and
10 l of the 60 l eluate were used.
RT-PCR amplification of plasma EIAV genome regions
containing CTLm epitopes
RT-PCR was performed using a SuperScript One-Step
RT-PCR kit (Life Technologies). Initial RT-PCR was per-
formed using 5 l template RNA eluate in 50 l total
reaction volume. When nested PCR was performed, 5 l
from the initial reaction was used in a 100 l total reaction
volume. The epitope Env-RW12 recognized by CTLm from
A2140 was contained within nt 5868-6164 and the follow-
ing primers and reaction conditions were used: outside for-
ward primer (5322F), 5-ATGGTCAGCATCGCATTC-3;
inside forward primer (5616F), 5-CAACATTATAT-
AGGGTTGGTAGC-3; reverse primer (6164R), 5-AG-
CAATCCCTTTCTCCTGT-3; initial RT-PCR, 30 min at
45°C, 2 min at 94°C, followed by 40 cycles of 30 s at 94°C,
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30 s at 59°C, 1 min at 72°C, and then 7 min at 72°C; nested
PCR, 2 min at 94°C, followed by 35 cycles of 30 s at 94°C,
30 s at 59°C, 45 s at 72°C, and then 7 min at 72°. The
epitope Gag-GW12 recognized by CTLm from A2140 was
contained within nt 406-694 and the following primers and
reaction conditions were used: forward primer (406F),
5-GACAGCAGAGGAGAACTTAC-3; reverse primer
(694R), 5-CCTCTCTTTCTTGTCCTG-3; 30 min at 45°C,
2 min at 94°C, followed by 40 cycles of 30 s at 94°C, 30 s
at 54°C, 30 s at 72°C, and then 7 min at 72°C. The epitope
Gag-FK10 recognized by CTLm from A2147 was contained
within nt 1141-1471 and the following primers and reaction
conditions were used: forward primer (1141F), 5-CCTAT-
TCCCATGACAGCAA-3; reverse primer (1471R), 5-
CCTCTGGTCTTAAATGTCTCATA-3; 40 min at 45°C, 2
min at 95°C, followed by 40 cycles of 30 s at 95°C, 30 s at
58°C, 30 s at 72°C, and then 7 min at 72°C. Finally, the Rev
epitopes recognized by CTLm from A2150 (Rev-QW11 and
Rev-PR12) and A2153 (Rev-IR10 and Rev-GR9) were con-
tained within nt 7143-7728 and the following primers and
reaction conditions were used: outside forward primer
(7143F), 5-GGAGTCATATTGGAAATTGGA-3; inside
forward primer (7175F), 5-GGGAGCTTCCATTATA-
AAATATAT-3; reverse primer (7728R), 5-CTAGTC-
CCCAAAATAGCCAT-3; initial RT-PCR, 40 min at
45°C, 2 min at 95°C, followed by 40 cycles of 30 s at 95°C,
30 s at 58°C, 45 s at 72°C, and then 7 min at 72°C; nested
PCR, 2 min at 95°C, followed by 40 cycles of 30 s at 95°C,
30 s at 58°C, 45 s at 72°C, and then 7 min at 72°C.
Cloning and sequencing of RT-PCR products
Amplified products from multiple RT-PCR reactions
were purified from agarose gels using a QIAquick Gel
Purification Kit (Qiagen) and cloned into the pCR2.1 TA
cloning vector (Invitrogen) (Zhang et al., 1999). A QIAprep
Spin Miniprep Kit (Qiagen) was used to extract plasmid
DNA from each of the clones, and the nucleotide sequences
determined by the Laboratory for Biotechnology and Bio-
analysis (Washington State University, Pullman, WA) using
an ABI Prism 377 (Applied Biosystems) automated DNA
sequencer. Deduced aa sequences from each of the EIAV
clones obtained were compared to the EIAVWSU5 consensus
sequence using ClustalW and Boxshade programs.
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